Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non Operating Income (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 10 years of Non Operating Income data on record, last reported at $2.4 million in Q4 2025.

  • For Q4 2025, Non Operating Income fell 69.1% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $20.8 million, down 28.51%, while the annual FY2025 figure was $20.8 million, 28.51% down from the prior year.
  • Non Operating Income reached $2.4 million in Q4 2025 per VRDN's latest filing, down from $5.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $7.7 million in Q4 2024 and bottomed at $34000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $3.6 million, with a median of $3.9 million recorded in 2023.
  • Peak YoY movement for Non Operating Income: skyrocketed 5669.86% in 2023, then tumbled 69.1% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $135000.0 in 2021, then surged by 2330.37% to $3.3 million in 2022, then soared by 40.75% to $4.6 million in 2023, then skyrocketed by 67.76% to $7.7 million in 2024, then crashed by 69.1% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $2.4 million in Q4 2025, $5.4 million in Q3 2025, and $6.0 million in Q2 2025.